Skip to main content

Compare Stocks

Date Range: 

 ChimerixBicycle TherapeuticsVBI VaccinesIntercept PharmaceuticalsSyndax Pharmaceuticals
SymbolNASDAQ:CMRXNASDAQ:BCYCNASDAQ:VBIVNASDAQ:ICPTNASDAQ:SNDX
Price Information
Current Price$8.17$30.36$2.86$17.75$17.92
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.71.31.52.21.8
Analysis Score4.53.53.64.13.4
Community Score2.42.43.23.12.5
Dividend Score0.00.00.00.00.0
Ownership Score1.70.80.83.32.5
Earnings & Valuation Score0.00.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$18.80$43.00$7.00$42.83$27.82
% Upside from Price Target130.11% upside41.63% upside144.76% upside141.27% upside55.24% upside
Trade Information
Market Cap$704.34 million$729.49 million$727.00 million$588.63 million$864.39 million
Beta1.88-0.212.141.851.8
Average Volume1,003,429163,4565,925,0491,145,946850,631
Sales & Book Value
Annual Revenue$12.52 million$13.80 million$2.22 million$252 million$1.52 million
Price / Sales56.2652.86327.482.34568.68
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.79 per share$5.27 per share$0.50 per share$1.57 per share$1.16 per share
Price / Book4.565.765.7211.3115.45
Profitability
Net Income$-112,580,000.00$-30,610,000.00$-54,810,000.00$-344,680,000.00$-56,050,000.00
EPS($0.86)($2.77)($0.46)($10.89)($1.84)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-321.31%-321.26%-2,837.73%-106.64%-4,656.63%
Return on Equity (ROE)-36.57%-42.73%-36.69%-1,973.10%-77.47%
Return on Assets (ROA)-33.53%-28.77%-28.29%-48.51%-52.27%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.13%0.10%N/A0.15%
Current Ratio12.18%9.63%9.06%3.44%11.71%
Quick Ratio12.18%9.63%8.95%3.44%11.71%
Ownership Information
Institutional Ownership Percentage45.41%42.68%52.13%85.77%83.78%
Insider Ownership Percentage9.00%26.30%10.50%23.70%9.50%
Miscellaneous
Employees548712749843
Shares Outstanding86.21 million24.03 million254.20 million33.16 million48.24 million
Next Earnings Date8/9/2021 (Estimated)8/4/2021 (Estimated)7/30/2021 (Estimated)8/9/2021 (Estimated)8/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Forecast: Bullish Sentiment Portends 74.72% Upside in 2021Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock Forecast: Bullish Sentiment Portends 74.72% Upside in 2021
stocksregister.com - May 12 at 5:27 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues  Earnings ResultsSyndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results
americanbankingnews.com - May 12 at 2:38 PM
Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia TrialSyndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial
finance.yahoo.com - May 12 at 12:27 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up  After Earnings BeatSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up After Earnings Beat
americanbankingnews.com - May 12 at 11:42 AM
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $20.00 Price Target at Morgan StanleySyndax Pharmaceuticals (NASDAQ:SNDX) Given New $20.00 Price Target at Morgan Stanley
americanbankingnews.com - May 12 at 11:08 AM
Recap: Syndax Pharmaceuticals Q1 EarningsRecap: Syndax Pharmaceuticals Q1 Earnings
benzinga.com - May 11 at 10:57 PM
Syndax Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call PresentationSyndax Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 11 at 7:36 PM
Syndax: Q1 Earnings SnapshotSyndax: Q1 Earnings Snapshot
chron.com - May 11 at 5:57 PM
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business UpdateSyndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
finance.yahoo.com - May 11 at 5:57 PM
DAX Stock News Today – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent – Marketing SentinelDAX Stock News Today – Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent – Marketing Sentinel
fintechzoom.com - May 8 at 3:00 PM
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be ImminentSyndax Pharmaceuticals Inc. (NASDAQ:SNDX) Jumps 4.97%, But Additional Rally May Be Imminent
marketingsentinel.com - May 8 at 9:59 AM
Syndax Pharmaceuticals Inc. (SNDX) has great growth outlook for 2021Syndax Pharmaceuticals Inc. (SNDX) has great growth outlook for 2021
marketingsentinel.com - May 5 at 10:58 AM
Syndax Pharmaceuticals (SNDX) to Release Earnings on TuesdaySyndax Pharmaceuticals (SNDX) to Release Earnings on Tuesday
americanbankingnews.com - May 5 at 10:56 AM
Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
finance.yahoo.com - May 4 at 7:35 AM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Buy" from BrokeragesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - May 3 at 2:58 AM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Here’s What’s Really Going OnSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX): Here’s What’s Really Going On
stocksregister.com - April 26 at 2:50 PM
Dennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On SharesDennis Podlesak Is The Independent Chairman of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) And Just Spent US$197k On Shares
finance.yahoo.com - April 25 at 8:57 AM
Syndax Pharmaceuticals Stock Appears To Be Significantly OvervaluedSyndax Pharmaceuticals Stock Appears To Be Significantly Overvalued
uk.finance.yahoo.com - April 24 at 8:04 AM
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 7.1% After Insider Buying ActivitySyndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Up 7.1% After Insider Buying Activity
americanbankingnews.com - April 23 at 10:28 AM
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 SharesSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Acquires 13,967 Shares
americanbankingnews.com - April 22 at 7:36 PM
Pre-earnings Bullish Momentum Pattern and Trigger in Syndax Pharmaceuticals IncPre-earnings Bullish Momentum Pattern and Trigger in Syndax Pharmaceuticals Inc
cmlviz.com - April 22 at 3:19 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down  Following Analyst DowngradeSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Down Following Analyst Downgrade
americanbankingnews.com - April 22 at 10:24 AM
Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?
finance.yahoo.com - April 22 at 10:18 AM
Wall Street Analyst Initiated Syndax Pharmaceuticals Inc. [SNDX]. What else is Wall St. sayingWall Street Analyst Initiated Syndax Pharmaceuticals Inc. [SNDX]. What else is Wall St. saying
dbtnews.com - April 21 at 11:34 PM
Syndax Pharmaceuticals (NASDAQ:SNDX) Sees Large Volume IncreaseSyndax Pharmaceuticals (NASDAQ:SNDX) Sees Large Volume Increase
americanbankingnews.com - April 21 at 12:58 PM
DateCompanyBrokerageAction
5/12/2021ChimerixHC WainwrightBoost Price Target
5/5/2021ChimerixMaxim GroupInitiated Coverage
4/12/2021ChimerixJonestradingReiterated Rating
3/31/2021ChimerixJefferies Financial GroupInitiated Coverage
3/31/2021ChimerixWedbushInitiated Coverage
5/9/2019ChimerixCowenReiterated Rating
3/6/2019ChimerixCitigroupLower Price Target
5/11/2021Bicycle TherapeuticsOppenheimerBoost Price Target
5/7/2021Bicycle TherapeuticsPiper SandlerBoost Price Target
4/26/2021Bicycle TherapeuticsJMP SecuritiesInitiated Coverage
1/20/2021Bicycle TherapeuticsCantor FitzgeraldBoost Price Target
9/10/2020Bicycle TherapeuticsCanaccord GenuityBoost Price Target
11/14/2019Bicycle TherapeuticsRoth CapitalInitiated Coverage
9/11/2019Bicycle TherapeuticsThe Goldman Sachs GroupUpgrade
8/26/2020VBI VaccinesRaymond JamesUpgrade
6/29/2020VBI VaccinesBMO Capital MarketsReiterated Rating
5/6/2021Intercept PharmaceuticalsStifel NicolausLower Price Target
3/8/2021Intercept PharmaceuticalsNeedham & Company LLCLower Price Target
3/1/2021Intercept PharmaceuticalsB. RileyLower Price Target
3/1/2021Intercept PharmaceuticalsChardan CapitalLower Price Target
1/15/2021Intercept PharmaceuticalsBank of AmericaDowngrade
5/13/2021Syndax PharmaceuticalsRobert W. BairdReiterated Rating
5/12/2021Syndax PharmaceuticalsMorgan StanleyLower Price Target
12/8/2020Syndax PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellBoost Price Target
12/8/2020Syndax PharmaceuticalsSmith Barney CitigroupBoost Price Target
12/7/2020Syndax PharmaceuticalsBTIG ResearchBoost Price Target
12/7/2020Syndax PharmaceuticalsBarclaysBoost Price Target
5/25/2020Syndax PharmaceuticalsNomuraReiterated Rating
(Data available from 5/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.